Tags

Type your tag names separated by a space and hit enter

Apolipoprotein assays: methodological considerations and studies in non-insulin-dependent diabetes treated by diet, glibenclamide and insulin.
Scand J Clin Lab Invest. 1989 May; 49(3):239-47.SJ

Abstract

The effect of sample pre-treatment as a source of variability of apolipoprotein (apo) AI, AII and B assays was demonstrated with lipid dissociating agents. The average mean percentage change ranged from -58 to +133% compared with untreated samples. The apolipoprotein method selected was validated by comparing their concentrations with their corresponding lipoprotein lipid or protein in normal controls and Type 2 (non-insulin-dependent) diabetic patients. The coefficient of variation was maintained below 3.5% for apo AI, AII, B and HDL2-apo AI. The apolipoprotein concentrations of fasting plasma lipoproteins were determined in a cross-sectional study of non-obese (body-mass index less than or equal to 30) patients with Type 2 diabetes mellitus. Compared with normal subjects matched for sex, age, body-mass index, exercise, alcohol consumption and smoking. Type 2 patients at diagnosis showed reduced apo AI and HDL2-apo AI concentrations, lowered apo AI:B ratio and increased concentrations of apo B. Type 2 patients treated by diet alone (for 6-72 months) and diet plus glibenclamide (2.5-15 mg/day for 6-48 months) exhibited similar abnormalities of plasma apolipoprotein concentration to Type 2 patients at diagnosis. However, in Type 2 patients treated with insulin (25-65 U/day for 8-144 months) concentrations of apo AI and HDL2-apo AI, and the apo AI:B ratio were normal. Apo B concentrations were generally lower compared with all groups of non-insulin treated patients. These abnormalities of apolipoprotein metabolism, which are associated with premature coronary disease, are still evident in patients treated by diet and diet plus glibenclamide, but are not seen in Type 2 patients treated with insulin.

Authors+Show Affiliations

Billingham MS
Department of Clinical Chemistry, Good Hope General Hospital, Birmingham, UK.
Milles JJ
No affiliation info available
Green A
No affiliation info available
Bailey CJ
No affiliation info available
Hall RA
No affiliation info available

MeSH

AdultApolipoprotein A-IApolipoproteins AApolipoproteins BDiabetes Mellitus, Type 2Diet, DiabeticFemaleGlyburideHumansInsulinMaleMiddle Aged

Pub Type(s)

Journal Article

Language

eng

PubMed ID

2500699

Citation

Billingham, M S., et al. "Apolipoprotein Assays: Methodological Considerations and Studies in Non-insulin-dependent Diabetes Treated By Diet, Glibenclamide and Insulin." Scandinavian Journal of Clinical and Laboratory Investigation, vol. 49, no. 3, 1989, pp. 239-47.
Billingham MS, Milles JJ, Green A, et al. Apolipoprotein assays: methodological considerations and studies in non-insulin-dependent diabetes treated by diet, glibenclamide and insulin. Scand J Clin Lab Invest. 1989;49(3):239-47.
Billingham, M. S., Milles, J. J., Green, A., Bailey, C. J., & Hall, R. A. (1989). Apolipoprotein assays: methodological considerations and studies in non-insulin-dependent diabetes treated by diet, glibenclamide and insulin. Scandinavian Journal of Clinical and Laboratory Investigation, 49(3), 239-47.
Billingham MS, et al. Apolipoprotein Assays: Methodological Considerations and Studies in Non-insulin-dependent Diabetes Treated By Diet, Glibenclamide and Insulin. Scand J Clin Lab Invest. 1989;49(3):239-47. PubMed PMID: 2500699.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Apolipoprotein assays: methodological considerations and studies in non-insulin-dependent diabetes treated by diet, glibenclamide and insulin. AU - Billingham,M S, AU - Milles,J J, AU - Green,A, AU - Bailey,C J, AU - Hall,R A, PY - 1989/5/1/pubmed PY - 1989/5/1/medline PY - 1989/5/1/entrez SP - 239 EP - 47 JF - Scandinavian journal of clinical and laboratory investigation JO - Scand J Clin Lab Invest VL - 49 IS - 3 N2 - The effect of sample pre-treatment as a source of variability of apolipoprotein (apo) AI, AII and B assays was demonstrated with lipid dissociating agents. The average mean percentage change ranged from -58 to +133% compared with untreated samples. The apolipoprotein method selected was validated by comparing their concentrations with their corresponding lipoprotein lipid or protein in normal controls and Type 2 (non-insulin-dependent) diabetic patients. The coefficient of variation was maintained below 3.5% for apo AI, AII, B and HDL2-apo AI. The apolipoprotein concentrations of fasting plasma lipoproteins were determined in a cross-sectional study of non-obese (body-mass index less than or equal to 30) patients with Type 2 diabetes mellitus. Compared with normal subjects matched for sex, age, body-mass index, exercise, alcohol consumption and smoking. Type 2 patients at diagnosis showed reduced apo AI and HDL2-apo AI concentrations, lowered apo AI:B ratio and increased concentrations of apo B. Type 2 patients treated by diet alone (for 6-72 months) and diet plus glibenclamide (2.5-15 mg/day for 6-48 months) exhibited similar abnormalities of plasma apolipoprotein concentration to Type 2 patients at diagnosis. However, in Type 2 patients treated with insulin (25-65 U/day for 8-144 months) concentrations of apo AI and HDL2-apo AI, and the apo AI:B ratio were normal. Apo B concentrations were generally lower compared with all groups of non-insulin treated patients. These abnormalities of apolipoprotein metabolism, which are associated with premature coronary disease, are still evident in patients treated by diet and diet plus glibenclamide, but are not seen in Type 2 patients treated with insulin. SN - 0036-5513 UR - https://www.unboundmedicine.com/medline/citation/2500699/Apolipoprotein_assays:_methodological_considerations_and_studies_in_non_insulin_dependent_diabetes_treated_by_diet_glibenclamide_and_insulin_ L2 - https://www.diseaseinfosearch.org/result/2236 DB - PRIME DP - Unbound Medicine ER -